Compare CVI & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CVI | CELC |
|---|---|---|
| Founded | 1906 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Integrated oil Companies | Medical Specialities |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.1B |
| IPO Year | 2006 | 2017 |
| Metric | CVI | CELC |
|---|---|---|
| Price | $31.38 | $120.31 |
| Analyst Decision | Strong Sell | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | $28.75 | ★ $107.88 |
| AVG Volume (30 Days) | ★ 1.0M | 673.7K |
| Earning Date | 04-29-2026 | 05-13-2026 |
| Dividend Yield | ★ 4.74% | N/A |
| EPS Growth | ★ 350.00 | N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $7,162,000,000.00 | N/A |
| Revenue This Year | $2.71 | N/A |
| Revenue Next Year | N/A | $720.19 |
| P/E Ratio | $116.78 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $17.95 | $9.64 |
| 52 Week High | $41.67 | $128.28 |
| Indicator | CVI | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 52.03 | 53.06 |
| Support Level | $28.79 | $99.38 |
| Resistance Level | $31.97 | N/A |
| Average True Range (ATR) | 1.56 | 6.94 |
| MACD | -0.27 | -0.34 |
| Stochastic Oscillator | 54.65 | 63.25 |
CVR Energy Inc is a holding company that engages in petroleum refining and nitrogen fertilizer manufacturing through its subsidiaries. Subsidiaries include several complex, full-coking crude oil refineries, along with a crude oil gathering system, pipelines, storage tanks, and marketing and supply. The company's refineries can process blends of a variety of crude oil ranging from heavy sour to light sweet crude oil. Crude oil for CVR's refineries is supplied through its wholly-owned gathering system and pipeline. From its refineries, CVR supplies products through tanker trucks directly to customers located in close geographic proximity and customers at throughput terminals. The company's customers include retailers, railroads, and farm cooperatives.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.